Skip to main content
NCBI home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 1996 Oct;55(10):700–714. doi: 10.1136/ard.55.10.700

Current and potential future drug treatments for osteoporosis.

S Patel 1
PMCID: PMC1010285  PMID: 8984934

Abstract

There has been a major interest in the drug treatment of osteoporosis and an increase in the number of drugs available in most countries. The ideal drug (one which increases or restores bone density and trabecular connectivity) is still not available. However, in patients with relatively preserved trabecular connectivity and moderately reduced bone density, several agents have shown substantial clinical benefit. Oestrogens are still the mainstay of drug treatment, but the risks of breast cancer versus the cardiovascular and skeletal benefits with long term use have to be assessed in the individual. Newer tissue specific oestrogens show some promise in this respect. The bisphosphonates and possibly fluoride are likely to be the major alternatives to oestrogens in the medium term. The newer bisphosphonates, alendronate and in the future risedronate, are likely to supersede etidronate. Calcitriol probably has a limited role, confined to those patients in whom HRT or bisphosphonates are not appropriate. Calcium supplementation, or an increase in dietary intake if deficient, irrespective of which agent is used, is also of benefit. In older patients there is considerable support for using a combination of calcium and vitamin D. Whether combination treatment, for example oestrogens, bisphosphonates, and calcium together, will result in greater efficacy remains to be conclusively shown, but may be an attractive option in younger patients with higher bone turnover. Apart from fluoride, bone formation stimulators are unlikely to have a major role until the next century, although it may be possible to use growth factors as part of an ADFR regimen (A = activate remodelling, D = depress resorption, F = free formation, and R = repeat). This is still an important theoretical approach and needs further work with newer agents to see if increased efficacy can be found. In addition sequential treatment may be necessary in view of the limited time periods over which particular agents, such as intermittent fluoride (four years), have been examined, and this will have to be individually tailored. Other approaches include trying to increase peak bone mineral density, although influencing the young to prevent a disease that may not manifest itself for half a century is daunting.

Full text

PDF
700

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adami S., Passeri M., Ortolani S., Broggini M., Carratelli L., Caruso I., Gandolini G., Gnessi L., Laurenzi M., Lombardi A. Effects of oral alendronate and intranasal salmon calcitonin on bone mass and biochemical markers of bone turnover in postmenopausal women with osteoporosis. Bone. 1995 Oct;17(4):383–390. doi: 10.1016/s8756-3282(95)00262-6. [DOI] [PubMed] [Google Scholar]
  2. Anderson F. H., Francis R. M., Faulkner K. Androgen supplementation in eugonadal men with osteoporosis-effects of 6 months of treatment on bone mineral density and cardiovascular risk factors. Bone. 1996 Feb;18(2):171–177. doi: 10.1016/8756-3282(95)00441-6. [DOI] [PubMed] [Google Scholar]
  3. Baillie S. P., Davison C. E., Johnson F. J., Francis R. M. Pathogenesis of vertebral crush fractures in men. Age Ageing. 1992 Mar;21(2):139–141. doi: 10.1093/ageing/21.2.139. [DOI] [PubMed] [Google Scholar]
  4. Barrett-Connor E. The economic and human costs of osteoporotic fracture. Am J Med. 1995 Feb 27;98(2A):3S–8S. doi: 10.1016/s0002-9343(05)80037-3. [DOI] [PubMed] [Google Scholar]
  5. Bell N. H. Vitamin D metabolism, aging, and bone loss. J Clin Endocrinol Metab. 1995 Apr;80(4):1051–1051. doi: 10.1210/jcem.80.4.7714064. [DOI] [PubMed] [Google Scholar]
  6. Bennett A. E., Wahner H. W., Riggs B. L., Hintz R. L. Insulin-like growth factors I and II: aging and bone density in women. J Clin Endocrinol Metab. 1984 Oct;59(4):701–704. doi: 10.1210/jcem-59-4-701. [DOI] [PubMed] [Google Scholar]
  7. Black L. J., Jones C. D., Falcone J. F. Antagonism of estrogen action with a new benzothiophene derived antiestrogen. Life Sci. 1983 Feb 28;32(9):1031–1036. doi: 10.1016/0024-3205(83)90935-9. [DOI] [PubMed] [Google Scholar]
  8. Black L. J., Sato M., Rowley E. R., Magee D. E., Bekele A., Williams D. C., Cullinan G. J., Bendele R., Kauffman R. F., Bensch W. R. Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats. J Clin Invest. 1994 Jan;93(1):63–69. doi: 10.1172/JCI116985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Brandi M. L. Flavonoids: biochemical effects and therapeutic applications. Bone Miner. 1992 Oct;19 (Suppl 1):S3–14. doi: 10.1016/0169-6009(92)90861-7. [DOI] [PubMed] [Google Scholar]
  10. Brandi M. L. New treatment strategies: ipriflavone, strontium, vitamin D metabolites and analogs. Am J Med. 1993 Nov 30;95(5A):69S–74S. doi: 10.1016/0002-9343(93)90386-4. [DOI] [PubMed] [Google Scholar]
  11. Brown E. M., Gamba G., Riccardi D., Lombardi M., Butters R., Kifor O., Sun A., Hediger M. A., Lytton J., Hebert S. C. Cloning and characterization of an extracellular Ca(2+)-sensing receptor from bovine parathyroid. Nature. 1993 Dec 9;366(6455):575–580. doi: 10.1038/366575a0. [DOI] [PubMed] [Google Scholar]
  12. Carrié Fässler A. L., Bonjour J. P. Osteoporosis as a pediatric problem. Pediatr Clin North Am. 1995 Aug;42(4):811–824. doi: 10.1016/s0031-3955(16)39018-6. [DOI] [PubMed] [Google Scholar]
  13. Centrella M., Horowitz M. C., Wozney J. M., McCarthy T. L. Transforming growth factor-beta gene family members and bone. Endocr Rev. 1994 Feb;15(1):27–39. doi: 10.1210/edrv-15-1-27. [DOI] [PubMed] [Google Scholar]
  14. Chapuy M. C., Arlot M. E., Duboeuf F., Brun J., Crouzet B., Arnaud S., Delmas P. D., Meunier P. J. Vitamin D3 and calcium to prevent hip fractures in the elderly women. N Engl J Med. 1992 Dec 3;327(23):1637–1642. doi: 10.1056/NEJM199212033272305. [DOI] [PubMed] [Google Scholar]
  15. Chen H. K., Ke H. Z., Jee W. S., Ma Y. F., Pirie C. M., Simmons H. A., Thompson D. D. Droloxifene prevents ovariectomy-induced bone loss in tibiae and femora of aged female rats: a dual-energy X-ray absorptiometric and histomorphometric study. J Bone Miner Res. 1995 Aug;10(8):1256–1262. doi: 10.1002/jbmr.5650100816. [DOI] [PubMed] [Google Scholar]
  16. Cheng S. L., Zhang S. F., Nelson T. L., Warlow P. M., Civitelli R. Stimulation of human osteoblast differentiation and function by ipriflavone and its metabolites. Calcif Tissue Int. 1994 Nov;55(5):356–362. doi: 10.1007/BF00299315. [DOI] [PubMed] [Google Scholar]
  17. Chesnut C. H., 3rd, McClung M. R., Ensrud K. E., Bell N. H., Genant H. K., Harris S. T., Singer F. R., Stock J. L., Yood R. A., Delmas P. D. Alendronate treatment of the postmenopausal osteoporotic woman: effect of multiple dosages on bone mass and bone remodeling. Am J Med. 1995 Aug;99(2):144–152. doi: 10.1016/s0002-9343(99)80134-x. [DOI] [PubMed] [Google Scholar]
  18. Christiansen C., Riis B. J. Five years with continuous combined oestrogen/progestogen therapy. Effects on calcium metabolism, lipoproteins, and bleeding pattern. Br J Obstet Gynaecol. 1990 Dec;97(12):1087–1092. doi: 10.1111/j.1471-0528.1990.tb02495.x. [DOI] [PubMed] [Google Scholar]
  19. Colditz G. A., Hankinson S. E., Hunter D. J., Willett W. C., Manson J. E., Stampfer M. J., Hennekens C., Rosner B., Speizer F. E. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med. 1995 Jun 15;332(24):1589–1593. doi: 10.1056/NEJM199506153322401. [DOI] [PubMed] [Google Scholar]
  20. Compston J. E. The role of vitamin D and calcium supplementation in the prevention of osteoporotic fractures in the elderly. Clin Endocrinol (Oxf) 1995 Oct;43(4):393–405. doi: 10.1111/j.1365-2265.1995.tb02609.x. [DOI] [PubMed] [Google Scholar]
  21. Cooper C., Campion G., Melton L. J., 3rd Hip fractures in the elderly: a world-wide projection. Osteoporos Int. 1992 Nov;2(6):285–289. doi: 10.1007/BF01623184. [DOI] [PubMed] [Google Scholar]
  22. Cooper G. J. Amylin compared with calcitonin gene-related peptide: structure, biology, and relevance to metabolic disease. Endocr Rev. 1994 Apr;15(2):163–201. doi: 10.1210/edrv-15-2-163. [DOI] [PubMed] [Google Scholar]
  23. Cornish J., Callon K. E., Cooper G. J., Reid I. R. Amylin stimulates osteoblast proliferation and increases mineralized bone volume in adult mice. Biochem Biophys Res Commun. 1995 Feb 6;207(1):133–139. doi: 10.1006/bbrc.1995.1163. [DOI] [PubMed] [Google Scholar]
  24. Crippes B. A., Engleman V. W., Settle S. L., Delarco J., Ornberg R. L., Helfrich M. H., Horton M. A., Nickols G. A. Antibody to beta3 integrin inhibits osteoclast-mediated bone resorption in the thyroparathyroidectomized rat. Endocrinology. 1996 Mar;137(3):918–924. doi: 10.1210/endo.137.3.8603604. [DOI] [PubMed] [Google Scholar]
  25. Dempster D. W. Bone histomorphometry in glucocorticoid-induced osteoporosis. J Bone Miner Res. 1989 Apr;4(2):137–141. doi: 10.1002/jbmr.5650040202. [DOI] [PubMed] [Google Scholar]
  26. Dempster D. W., Cosman F., Parisien M., Shen V., Lindsay R. Anabolic actions of parathyroid hormone on bone. Endocr Rev. 1993 Dec;14(6):690–709. doi: 10.1210/edrv-14-6-690. [DOI] [PubMed] [Google Scholar]
  27. Devogelaer J. P., Broll H., Correa-Rotter R., Cumming D. C., De Deuxchaisnes C. N., Geusens P., Hosking D., Jaeger P., Kaufman J. M., Leite M. Oral alendronate induces progressive increases in bone mass of the spine, hip, and total body over 3 years in postmenopausal women with osteoporosis. Bone. 1996 Feb;18(2):141–150. doi: 10.1016/8756-3282(95)00436-x. [DOI] [PubMed] [Google Scholar]
  28. Eastell R. Management of corticosteroid-induced osteoporosis. UK Consensus Group Meeting on Osteoporosis. J Intern Med. 1995 May;237(5):439–447. doi: 10.1111/j.1365-2796.1995.tb00868.x. [DOI] [PubMed] [Google Scholar]
  29. Ebeling P. R., Jones J. D., O'Fallon W. M., Janes C. H., Riggs B. L. Short-term effects of recombinant human insulin-like growth factor I on bone turnover in normal women. J Clin Endocrinol Metab. 1993 Nov;77(5):1384–1387. doi: 10.1210/jcem.77.5.8077337. [DOI] [PubMed] [Google Scholar]
  30. Effect of fluoride in postmenopausal osteoporosis. N Engl J Med. 1990 Aug 9;323(6):416–417. doi: 10.1056/NEJM199008093230612. [DOI] [PubMed] [Google Scholar]
  31. Evans G., Bryant H. U., Magee D., Sato M., Turner R. T. The effects of raloxifene on tibia histomorphometry in ovariectomized rats. Endocrinology. 1994 May;134(5):2283–2288. doi: 10.1210/endo.134.5.8156931. [DOI] [PubMed] [Google Scholar]
  32. Filipponi P., Cristallini S., Rizzello E., Policani G., Fedeli L., Gregorio F., Boldrini S., Troiani S., Massoni C. Cyclical intravenous clodronate in postmenopausal osteoporosis: results of a long-term clinical trial. Bone. 1996 Feb;18(2):179–184. doi: 10.1016/8756-3282(95)00442-4. [DOI] [PubMed] [Google Scholar]
  33. Filipponi P., Pedetti M., Fedeli L., Cini L., Palumbo R., Boldrini S., Massoni C., Cristallini S. Cyclical clodronate is effective in preventing postmenopausal bone loss: a comparative study with transcutaneous hormone replacement therapy. J Bone Miner Res. 1995 May;10(5):697–703. doi: 10.1002/jbmr.5650100505. [DOI] [PubMed] [Google Scholar]
  34. Fleisch H. The use of bisphosphonates in osteoporosis. Br J Clin Pract. 1994 Nov-Dec;48(6):323–326. [PubMed] [Google Scholar]
  35. Frost H. M. Treatment of osteoporoses by manipulation of coherent bone cell populations. Clin Orthop Relat Res. 1979 Sep;(143):227–244. [PubMed] [Google Scholar]
  36. Gallagher J. C., Kable W. T., Goldgar D. Effect of progestin therapy on cortical and trabecular bone: comparison with estrogen. Am J Med. 1991 Feb;90(2):171–178. [PubMed] [Google Scholar]
  37. Gambacciani M., Spinetti A., Cappagli B., Taponeco F., Felipetto R., Parrini D., Cappelli N., Fioretti P. Effects of ipriflavone administration on bone mass and metabolism in ovariectomized women. J Endocrinol Invest. 1993 May;16(5):333–337. doi: 10.1007/BF03348848. [DOI] [PubMed] [Google Scholar]
  38. Genazzani A. R., Benedek-Jaszmann L. J., Hart D. M., Andolsek L., Kicovic P. M., Tax L. Org OD 14 and the endometrium. Maturitas. 1991 Sep;13(3):243–251. doi: 10.1016/0378-5122(91)90199-z. [DOI] [PubMed] [Google Scholar]
  39. Gennari C., Agnusdei D. Calcitonins and osteoporosis. Br J Clin Pract. 1994 Jul-Aug;48(4):196–200. [PubMed] [Google Scholar]
  40. Geusens P., Dequeker J., Gielen J., Schot L. P. Non-linear increase in vertebral density induced by a synthetic steroid (Org OD 14) in women with established osteoporosis. Maturitas. 1991 Jun;13(2):155–162. doi: 10.1016/0378-5122(91)90099-c. [DOI] [PubMed] [Google Scholar]
  41. Giannini S., D'Angelo A., Malvasi L., Castrignano R., Pati T., Tronca R., Liberto L., Nobile M., Crepaldi G. Effects of one-year cyclical treatment with clodronate on postmenopausal bone loss. Bone. 1993 Mar-Apr;14(2):137–141. doi: 10.1016/8756-3282(93)90240-b. [DOI] [PubMed] [Google Scholar]
  42. Gough A. K., Lilley J., Eyre S., Holder R. L., Emery P. Generalised bone loss in patients with early rheumatoid arthritis. Lancet. 1994 Jul 2;344(8914):23–27. doi: 10.1016/s0140-6736(94)91049-9. [DOI] [PubMed] [Google Scholar]
  43. Grey A. B., Cundy T. F., Reid I. R. Continuous combined oestrogen/progestin therapy is well tolerated and increases bone density at the hip and spine in post-menopausal osteoporosis. Clin Endocrinol (Oxf) 1994 May;40(5):671–677. doi: 10.1111/j.1365-2265.1994.tb03020.x. [DOI] [PubMed] [Google Scholar]
  44. Grey A. B., Stapleton J. P., Evans M. C., Tatnell M. A., Ames R. W., Reid I. R. The effect of the antiestrogen tamoxifen on bone mineral density in normal late postmenopausal women. Am J Med. 1995 Dec;99(6):636–641. doi: 10.1016/s0002-9343(99)80251-4. [DOI] [PubMed] [Google Scholar]
  45. Grey A., Cundy T., Evans M., Reid I. Medroxyprogesterone acetate enhances the spinal bone mineral density response to oestrogen in late post-menopausal women. Clin Endocrinol (Oxf) 1996 Mar;44(3):293–296. doi: 10.1046/j.1365-2265.1996.667488.x. [DOI] [PubMed] [Google Scholar]
  46. Grotz W. H., Mundinger F. A., Gugel B., Exner V. M., Kirste G., Schollmeyer P. J. Bone mineral density after kidney transplantation. A cross-sectional study in 190 graft recipients up to 20 years after transplantation. Transplantation. 1995 Apr 15;59(7):982–986. [PubMed] [Google Scholar]
  47. Harris S. T., Watts N. B., Jackson R. D., Genant H. K., Wasnich R. D., Ross P., Miller P. D., Licata A. A., Chesnut C. H., 3rd Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: three years of blinded therapy followed by one year of open therapy. Am J Med. 1993 Dec;95(6):557–567. doi: 10.1016/0002-9343(93)90350-x. [DOI] [PubMed] [Google Scholar]
  48. Heaney R. P. Bone mass, nutrition, and other lifestyle factors. Am J Med. 1993 Nov 30;95(5A):29S–33S. doi: 10.1016/0002-9343(93)90378-3. [DOI] [PubMed] [Google Scholar]
  49. Heaney R. P. Interpreting trials of bone-active agents. Am J Med. 1995 Apr;98(4):329–330. doi: 10.1016/S0002-9343(99)80309-X. [DOI] [PubMed] [Google Scholar]
  50. Hermus A. R., Smals A. G., Swinkels L. M., Huysmans D. A., Pieters G. F., Sweep C. F., Corstens F. H., Kloppenborg P. W. Bone mineral density and bone turnover before and after surgical cure of Cushing's syndrome. J Clin Endocrinol Metab. 1995 Oct;80(10):2859–2865. doi: 10.1210/jcem.80.10.7559865. [DOI] [PubMed] [Google Scholar]
  51. Hewison M. New trends in bone research. J R Coll Physicians Lond. 1995 Sep-Oct;29(5):383–387. [PMC free article] [PubMed] [Google Scholar]
  52. Hill P. A., Reynolds J. J., Meikle M. C. Osteoblasts mediate insulin-like growth factor-I and -II stimulation of osteoclast formation and function. Endocrinology. 1995 Jan;136(1):124–131. doi: 10.1210/endo.136.1.7828521. [DOI] [PubMed] [Google Scholar]
  53. Horowitz M., Wishart J. M., Need A. G., Morris H. A., Nordin B. E. Effects of norethisterone on bone related biochemical variables and forearm bone mineral in post-menopausal osteoporosis. Clin Endocrinol (Oxf) 1993 Dec;39(6):649–655. doi: 10.1111/j.1365-2265.1993.tb02422.x. [DOI] [PubMed] [Google Scholar]
  54. Inzucchi S. E., Robbins R. J. Clinical review 61: Effects of growth hormone on human bone biology. J Clin Endocrinol Metab. 1994 Sep;79(3):691–694. doi: 10.1210/jcem.79.3.8077348. [DOI] [PubMed] [Google Scholar]
  55. Ismail S. M. Effects of tamoxifen on uterus. Lancet. 1994 Aug 27;344(8922):622–623. doi: 10.1016/s0140-6736(94)92013-3. [DOI] [PubMed] [Google Scholar]
  56. Johansen J. S., Hassager C., Pødenphant J., Riis B. J., Hartwell D., Thomsen K., Christiansen C. Treatment of postmenopausal osteoporosis: is the anabolic steroid nandrolone decanoate a candidate? Bone Miner. 1989 Apr;6(1):77–86. doi: 10.1016/0169-6009(89)90025-1. [DOI] [PubMed] [Google Scholar]
  57. Johansson A. G., Lindh E., Ljunghall S. Growth hormone, insulin-like growth factor I, and bone: a clinical review. J Intern Med. 1993 Dec;234(6):553–560. doi: 10.1111/j.1365-2796.1993.tb01013.x. [DOI] [PubMed] [Google Scholar]
  58. Johansson A. G., Lindh E., Ljunghall S. Insulin-like growth factor I stimulates bone turnover in osteoporosis. Lancet. 1992 Jun 27;339(8809):1619–1619. doi: 10.1016/0140-6736(92)91889-g. [DOI] [PubMed] [Google Scholar]
  59. Kanis J. A., Adami S. Bone loss in the elderly. Osteoporos Int. 1994;4 (Suppl 1):59–65. doi: 10.1007/BF01623438. [DOI] [PubMed] [Google Scholar]
  60. Ke H. Z., Simmons H. A., Pirie C. M., Crawford D. T., Thompson D. D. Droloxifene, a new estrogen antagonist/agonist, prevents bone loss in ovariectomized rats. Endocrinology. 1995 Jun;136(6):2435–2441. doi: 10.1210/endo.136.6.7750465. [DOI] [PubMed] [Google Scholar]
  61. Keeting P. E., Oursler M. J., Wiegand K. E., Bonde S. K., Spelsberg T. C., Riggs B. L. Zeolite A increases proliferation, differentiation, and transforming growth factor beta production in normal adult human osteoblast-like cells in vitro. J Bone Miner Res. 1992 Nov;7(11):1281–1289. doi: 10.1002/jbmr.5650071107. [DOI] [PubMed] [Google Scholar]
  62. King K. L., D'Anza J. J., Bodary S., Pitti R., Siegel M., Lazarus R. A., Dennis M. S., Hammonds R. G., Jr, Kukreja S. C. Effects of kistrin on bone resorption in vitro and serum calcium in vivo. J Bone Miner Res. 1994 Mar;9(3):381–387. doi: 10.1002/jbmr.5650090313. [DOI] [PubMed] [Google Scholar]
  63. Kleerekoper M., Peterson E. L., Nelson D. A., Phillips E., Schork M. A., Tilley B. C., Parfitt A. M. A randomized trial of sodium fluoride as a treatment for postmenopausal osteoporosis. Osteoporos Int. 1991 Jun;1(3):155–161. doi: 10.1007/BF01625446. [DOI] [PubMed] [Google Scholar]
  64. Kleerekopper M., Schiebinger R. J. Skeletal recovery after treatment of Cushing's: still room for improvement. J Clin Endocrinol Metab. 1995 Oct;80(10):2856–2858. doi: 10.1210/jcem.80.10.7559864. [DOI] [PubMed] [Google Scholar]
  65. Kovács A. B. Efficacy of ipriflavone in the prevention and treatment of postmenopausal osteoporosis. Agents Actions. 1994 Mar;41(1-2):86–87. doi: 10.1007/BF01986400. [DOI] [PubMed] [Google Scholar]
  66. Liberman U. A., Weiss S. R., Bröll J., Minne H. W., Quan H., Bell N. H., Rodriguez-Portales J., Downs R. W., Jr, Dequeker J., Favus M. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med. 1995 Nov 30;333(22):1437–1443. doi: 10.1056/NEJM199511303332201. [DOI] [PubMed] [Google Scholar]
  67. Lindsay R. Fluoride and bone--quantity versus quality. N Engl J Med. 1990 Mar 22;322(12):845–846. doi: 10.1056/NEJM199003223221210. [DOI] [PubMed] [Google Scholar]
  68. Lindsay R., Hart D. M., Kraszewski A. Prospective double-blind trial of synthetic steroid (Org OD 14) for preventing postmenopausal osteoporosis. Br Med J. 1980 May 17;280(6225):1207–1209. doi: 10.1136/bmj.280.6225.1207. [DOI] [PMC free article] [PubMed] [Google Scholar]
  69. Ljunghall S., Johansson A. G., Burman P., Kämpe O., Lindh E., Karlsson F. A. Low plasma levels of insulin-like growth factor 1 (IGF-1) in male patients with idiopathic osteoporosis. J Intern Med. 1992 Jul;232(1):59–64. doi: 10.1111/j.1365-2796.1992.tb00550.x. [DOI] [PubMed] [Google Scholar]
  70. Lobo R. A. Benefits and risks of estrogen replacement therapy. Am J Obstet Gynecol. 1995 Sep;173(3 Pt 2):982–989. doi: 10.1016/0002-9378(95)90247-3. [DOI] [PubMed] [Google Scholar]
  71. Lobo R. A. Clinical review 27: Effects of hormonal replacement on lipids and lipoproteins in postmenopausal women. J Clin Endocrinol Metab. 1991 Nov;73(5):925–930. doi: 10.1210/jcem-73-5-925. [DOI] [PubMed] [Google Scholar]
  72. Luengo M., Picado C., Del Rio L., Guañabens N., Montserrat J. M., Setoain J. Treatment of steroid-induced osteopenia with calcitonin in corticosteroid-dependent asthma. A one-year follow-up study. Am Rev Respir Dis. 1990 Jul;142(1):104–107. doi: 10.1164/ajrccm/142.1.104. [DOI] [PubMed] [Google Scholar]
  73. Mackie E. J., Trechsel U. Stimulation of bone formation in vivo by transforming growth factor-beta: remodeling of woven bone and lack of inhibition by indomethacin. Bone. 1990;11(4):295–300. doi: 10.1016/8756-3282(90)90083-b. [DOI] [PubMed] [Google Scholar]
  74. Marie P. J., Hott M., Modrowski D., De Pollak C., Guillemain J., Deloffre P., Tsouderos Y. An uncoupling agent containing strontium prevents bone loss by depressing bone resorption and maintaining bone formation in estrogen-deficient rats. J Bone Miner Res. 1993 May;8(5):607–615. doi: 10.1002/jbmr.5650080512. [DOI] [PubMed] [Google Scholar]
  75. McDonald C. C., Alexander F. E., Whyte B. W., Forrest A. P., Stewart H. J. Cardiac and vascular morbidity in women receiving adjuvant tamoxifen for breast cancer in a randomised trial. The Scottish Cancer Trials Breast Group. BMJ. 1995 Oct 14;311(7011):977–980. doi: 10.1136/bmj.311.7011.977. [DOI] [PMC free article] [PubMed] [Google Scholar]
  76. Meys E., Terreaux-Duvert F., Beaume-Six T., Dureau G., Meunier P. J. Bone loss after cardiac transplantation: effects of calcium, calcidiol and monofluorophosphate. Osteoporos Int. 1993 Dec;3(6):322–329. doi: 10.1007/BF01637318. [DOI] [PubMed] [Google Scholar]
  77. Mochizuki H., Hakeda Y., Wakatsuki N., Usui N., Akashi S., Sato T., Tanaka K., Kumegawa M. Insulin-like growth factor-I supports formation and activation of osteoclasts. Endocrinology. 1992 Sep;131(3):1075–1080. doi: 10.1210/endo.131.3.1505451. [DOI] [PubMed] [Google Scholar]
  78. Mohan S., Baylink D. J. Bone growth factors. Clin Orthop Relat Res. 1991 Feb;(263):30–48. [PubMed] [Google Scholar]
  79. Mulder H., Struys A. Intermittent cyclical etidronate in the prevention of corticosteroid-induced bone loss. Br J Rheumatol. 1994 Apr;33(4):348–350. doi: 10.1093/rheumatology/33.4.348. [DOI] [PubMed] [Google Scholar]
  80. Nicolas V., Mohan S., Honda Y., Prewett A., Finkelman R. D., Baylink D. J., Farley J. R. An age-related decrease in the concentration of insulin-like growth factor binding protein-5 in human cortical bone. Calcif Tissue Int. 1995 Sep;57(3):206–212. doi: 10.1007/BF00310260. [DOI] [PubMed] [Google Scholar]
  81. Nicolas V., Prewett A., Bettica P., Mohan S., Finkelman R. D., Baylink D. J., Farley J. R. Age-related decreases in insulin-like growth factor-I and transforming growth factor-beta in femoral cortical bone from both men and women: implications for bone loss with aging. J Clin Endocrinol Metab. 1994 May;78(5):1011–1016. doi: 10.1210/jcem.78.5.8175953. [DOI] [PubMed] [Google Scholar]
  82. Olbricht T., Benker G. Glucocorticoid-induced osteoporosis: pathogenesis, prevention and treatment, with special regard to the rheumatic diseases. J Intern Med. 1993 Sep;234(3):237–244. doi: 10.1111/j.1365-2796.1993.tb00738.x. [DOI] [PubMed] [Google Scholar]
  83. Olgaard K., Storm T., van Wowern N., Daugaard H., Egfjord M., Lewin E., Brandi L. Glucocorticoid-induced osteoporosis in the lumbar spine, forearm, and mandible of nephrotic patients: a double-blind study on the high-dose, long-term effects of prednisone versus deflazacort. Calcif Tissue Int. 1992 Jun;50(6):490–497. doi: 10.1007/BF00582160. [DOI] [PubMed] [Google Scholar]
  84. Ooms M. E., Roos J. C., Bezemer P. D., van der Vijgh W. J., Bouter L. M., Lips P. Prevention of bone loss by vitamin D supplementation in elderly women: a randomized double-blind trial. J Clin Endocrinol Metab. 1995 Apr;80(4):1052–1058. doi: 10.1210/jcem.80.4.7714065. [DOI] [PubMed] [Google Scholar]
  85. Orimo H., Shiraki M., Hayashi Y., Hoshino T., Onaya T., Miyazaki S., Kurosawa H., Nakamura T., Ogawa N. Effects of 1 alpha-hydroxyvitamin D3 on lumbar bone mineral density and vertebral fractures in patients with postmenopausal osteoporosis. Calcif Tissue Int. 1994 May;54(5):370–376. doi: 10.1007/BF00305521. [DOI] [PubMed] [Google Scholar]
  86. Orwoll E. S., Klein R. F. Osteoporosis in men. Endocr Rev. 1995 Feb;16(1):87–116. doi: 10.1210/edrv-16-1-87. [DOI] [PubMed] [Google Scholar]
  87. Ott S. M. Bone mass measurements: reasons to be cautious. BMJ. 1994 Apr 9;308(6934):931–932. doi: 10.1136/bmj.308.6934.931. [DOI] [PMC free article] [PubMed] [Google Scholar]
  88. Oursler M. J., Spelsberg T. C. Echistatin, a potential new drug for osteoporosis. Endocrinology. 1993 Mar;132(3):939–940. doi: 10.1210/endo.132.3.8440196. [DOI] [PubMed] [Google Scholar]
  89. Overgaard K., Riis B. J. Nasal salmon calcitonin in osteoporosis. Calcif Tissue Int. 1994 Aug;55(2):79–81. doi: 10.1007/BF00297178. [DOI] [PubMed] [Google Scholar]
  90. Pak C. Y., Sakhaee K., Adams-Huet B., Piziak V., Peterson R. D., Poindexter J. R. Treatment of postmenopausal osteoporosis with slow-release sodium fluoride. Final report of a randomized controlled trial. Ann Intern Med. 1995 Sep 15;123(6):401–408. doi: 10.7326/0003-4819-123-6-199509150-00001. [DOI] [PubMed] [Google Scholar]
  91. Peris P., Guañabens N., Monegal A., Suris X., Alvarez L., Martinez de Osaba M. J., Hernandez M. V., Muñoz-Gomez J. Aetiology and presenting symptoms in male osteoporosis. Br J Rheumatol. 1995 Oct;34(10):936–941. doi: 10.1093/rheumatology/34.10.936. [DOI] [PubMed] [Google Scholar]
  92. Pocock N. A., Eisman J. A., Dunstan C. R., Evans R. A., Thomas D. H., Huq N. L. Recovery from steroid-induced osteoporosis. Ann Intern Med. 1987 Sep;107(3):319–323. doi: 10.7326/0003-4819-107-2-319. [DOI] [PubMed] [Google Scholar]
  93. Pors Nielsen S., Bärenholdt O., Hermansen F., Munk-Jensen N. Magnitude and pattern of skeletal response to long term continuous and cyclic sequential oestrogen/progestin treatment. Br J Obstet Gynaecol. 1994 Apr;101(4):319–324. doi: 10.1111/j.1471-0528.1994.tb13618.x. [DOI] [PubMed] [Google Scholar]
  94. Powles T. J., Hickish T., Kanis J. A., Tidy A., Ashley S. Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol. 1996 Jan;14(1):78–84. doi: 10.1200/JCO.1996.14.1.78. [DOI] [PubMed] [Google Scholar]
  95. Pun K. K., Chan L. W. Analgesic effect of intranasal salmon calcitonin in the treatment of osteoporotic vertebral fractures. Clin Ther. 1989 Mar-Apr;11(2):205–209. [PubMed] [Google Scholar]
  96. Reed B. Y., Zerwekh J. E., Sakhaee K., Breslau N. A., Gottschalk F., Pak C. Y. Serum IGF 1 is low and correlated with osteoblastic surface in idiopathic osteoporosis. J Bone Miner Res. 1995 Aug;10(8):1218–1224. doi: 10.1002/jbmr.5650100812. [DOI] [PubMed] [Google Scholar]
  97. Reginster J. Y. Ipriflavone: pharmacological properties and usefulness in postmenopausal osteoporosis. Bone Miner. 1993 Dec;23(3):223–232. doi: 10.1016/s0169-6009(08)80099-2. [DOI] [PubMed] [Google Scholar]
  98. Reid I. R., Ames R. W., Evans M. C., Gamble G. D., Sharpe S. J. Long-term effects of calcium supplementation on bone loss and fractures in postmenopausal women: a randomized controlled trial. Am J Med. 1995 Apr;98(4):331–335. doi: 10.1016/S0002-9343(99)80310-6. [DOI] [PubMed] [Google Scholar]
  99. Reid I. R., Grey A. B. Corticosteroid osteoporosis. Baillieres Clin Rheumatol. 1993 Oct;7(3):573–587. doi: 10.1016/s0950-3579(05)80080-9. [DOI] [PubMed] [Google Scholar]
  100. Reid I. R., Heap S. W. Determinants of vertebral mineral density in patients receiving long-term glucocorticoid therapy. Arch Intern Med. 1990 Dec;150(12):2545–2548. [PubMed] [Google Scholar]
  101. Reid I. R., Ibbertson H. K. Calcium supplements in the prevention of steroid-induced osteoporosis. Am J Clin Nutr. 1986 Aug;44(2):287–290. doi: 10.1093/ajcn/44.2.287. [DOI] [PubMed] [Google Scholar]
  102. Reid I. R., Wattie D. J., Evans M. C., Gamble G. D., Stapleton J. P., Cornish J. Continuous therapy with pamidronate, a potent bisphosphonate, in postmenopausal osteoporosis. J Clin Endocrinol Metab. 1994 Dec;79(6):1595–1599. doi: 10.1210/jcem.79.6.7989461. [DOI] [PubMed] [Google Scholar]
  103. Riggs B. L., Hodgson S. F., O'Fallon W. M., Chao E. Y., Wahner H. W., Muhs J. M., Cedel S. L., Melton L. J., 3rd Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis. N Engl J Med. 1990 Mar 22;322(12):802–809. doi: 10.1056/NEJM199003223221203. [DOI] [PubMed] [Google Scholar]
  104. Riggs B. L., Melton L. J., 3rd The prevention and treatment of osteoporosis. N Engl J Med. 1992 Aug 27;327(9):620–627. doi: 10.1056/NEJM199208273270908. [DOI] [PubMed] [Google Scholar]
  105. Riggs B. L., O'Fallon W. M., Lane A., Hodgson S. F., Wahner H. W., Muhs J., Chao E., Melton L. J., 3rd Clinical trial of fluoride therapy in postmenopausal osteoporotic women: extended observations and additional analysis. J Bone Miner Res. 1994 Feb;9(2):265–275. doi: 10.1002/jbmr.5650090216. [DOI] [PubMed] [Google Scholar]
  106. Ringe J. D., Meunier P. J. What is the future for fluoride in the treatment of osteoporosis? Osteoporos Int. 1995 Mar;5(2):71–74. doi: 10.1007/BF01623306. [DOI] [PubMed] [Google Scholar]
  107. Rosen C. J. Growth hormone, insulin-like growth factors, and the senescent skeleton: Ponce de Leon's Fountain revisited? J Cell Biochem. 1994 Nov;56(3):348–356. doi: 10.1002/jcb.240560311. [DOI] [PubMed] [Google Scholar]
  108. Rubin C. D., Reed B., Sakhaee K., Pak C. Y. Treating a patient with the Werner syndrome and osteoporosis using recombinant human insulin-like growth factor. Ann Intern Med. 1994 Nov 1;121(9):665–668. doi: 10.7326/0003-4819-121-9-199411010-00007. [DOI] [PubMed] [Google Scholar]
  109. Rudman D., Feller A. G., Nagraj H. S., Gergans G. A., Lalitha P. Y., Goldberg A. F., Schlenker R. A., Cohn L., Rudman I. W., Mattson D. E. Effects of human growth hormone in men over 60 years old. N Engl J Med. 1990 Jul 5;323(1):1–6. doi: 10.1056/NEJM199007053230101. [DOI] [PubMed] [Google Scholar]
  110. Rymer J., Chapman M. G., Fogelman I. Effect of tibolone on postmenopausal bone loss. Osteoporos Int. 1994 Nov;4(6):314–319. doi: 10.1007/BF01622189. [DOI] [PubMed] [Google Scholar]
  111. Sambrook P. N., Kelly P. J., Keogh A. M., Macdonald P., Spratt P., Freund J., Eisman J. A. Bone loss after heart transplantation: a prospective study. J Heart Lung Transplant. 1994 Jan-Feb;13(1 Pt 1):116–121. [PubMed] [Google Scholar]
  112. Sambrook P., Birmingham J., Kelly P., Kempler S., Nguyen T., Pocock N., Eisman J. Prevention of corticosteroid osteoporosis. A comparison of calcium, calcitriol, and calcitonin. N Engl J Med. 1993 Jun 17;328(24):1747–1752. doi: 10.1056/NEJM199306173282404. [DOI] [PubMed] [Google Scholar]
  113. Sato M., Kim J., Short L. L., Slemenda C. W., Bryant H. U. Longitudinal and cross-sectional analysis of raloxifene effects on tibiae from ovariectomized aged rats. J Pharmacol Exp Ther. 1995 Mar;272(3):1252–1259. [PubMed] [Google Scholar]
  114. Sato M., McClintock C., Kim J., Turner C. H., Bryant H. U., Magee D., Slemenda C. W. Dual-energy x-ray absorptiometry of raloxifene effects on the lumbar vertebrae and femora of ovariectomized rats. J Bone Miner Res. 1994 May;9(5):715–724. doi: 10.1002/jbmr.5650090517. [DOI] [PubMed] [Google Scholar]
  115. Schmid C. The regulation of osteoblast function by hormones and cytokines with special reference to insulin-like growth factors and their binding proteins. J Intern Med. 1993 Dec;234(6):535–542. doi: 10.1111/j.1365-2796.1993.tb01011.x. [DOI] [PubMed] [Google Scholar]
  116. Seeman E. The dilemma of osteoporosis in men. Am J Med. 1995 Feb 27;98(2A):76S–88S. doi: 10.1016/s0002-9343(05)80082-8. [DOI] [PubMed] [Google Scholar]
  117. Selby P. L. Calcium requirement--a reappraisal of the methods used in its determination and their application to patients with osteoporosis. Am J Clin Nutr. 1994 Dec;60(6):944–948. doi: 10.1093/ajcn/60.6.944. [DOI] [PubMed] [Google Scholar]
  118. Shiraki M., Ito H., Orimo H. The ultra long-term treatment of senile osteoporosis with 1 alpha-hydroxyvitamin D3. Bone Miner. 1993 Mar;20(3):223–234. doi: 10.1016/s0169-6009(08)80003-7. [DOI] [PubMed] [Google Scholar]
  119. Stanford J. L., Weiss N. S., Voigt L. F., Daling J. R., Habel L. A., Rossing M. A. Combined estrogen and progestin hormone replacement therapy in relation to risk of breast cancer in middle-aged women. JAMA. 1995 Jul 12;274(2):137–142. [PubMed] [Google Scholar]
  120. Storm T., Thamsborg G., Steiniche T., Genant H. K., Sørensen O. H. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N Engl J Med. 1990 May 3;322(18):1265–1271. doi: 10.1056/NEJM199005033221803. [DOI] [PubMed] [Google Scholar]
  121. Tilyard M. W., Spears G. F., Thomson J., Dovey S. Treatment of postmenopausal osteoporosis with calcitriol or calcium. N Engl J Med. 1992 Feb 6;326(6):357–362. doi: 10.1056/NEJM199202063260601. [DOI] [PubMed] [Google Scholar]
  122. Tsurukami H., Nakamura T., Suzuki K., Sato K., Higuchi Y., Nishii Y. A novel synthetic vitamin D analogue, 2 beta-(3-hydroxypropoxy)1 alpha, 25-dihydroxyvitamin D3 (ED-71), increases bone mass by stimulating the bone formation in normal and ovariectomized rats. Calcif Tissue Int. 1994 Feb;54(2):142–149. doi: 10.1007/BF00296065. [DOI] [PubMed] [Google Scholar]
  123. Turner C. H., Sato M., Bryant H. U. Raloxifene preserves bone strength and bone mass in ovariectomized rats. Endocrinology. 1994 Nov;135(5):2001–2005. doi: 10.1210/endo.135.5.7956922. [DOI] [PubMed] [Google Scholar]
  124. Turner C. H. Toward a cure for osteoporosis: reversal of excessive bone fragility. Osteoporos Int. 1991 Oct;2(1):12–19. doi: 10.1007/BF01627073. [DOI] [PubMed] [Google Scholar]
  125. Valente M., Bufalino L., Castiglione G. N., D'Angelo R., Mancuso A., Galoppi P., Zichella L. Effects of 1-year treatment with ipriflavone on bone in postmenopausal women with low bone mass. Calcif Tissue Int. 1994 May;54(5):377–380. doi: 10.1007/BF00305522. [DOI] [PubMed] [Google Scholar]
  126. Vänänen H. K., Karhukorpi E. K., Sundquist K., Wallmark B., Roininen I., Hentunen T., Tuukkanen J., Lakkakorpi P. Evidence for the presence of a proton pump of the vacuolar H(+)-ATPase type in the ruffled borders of osteoclasts. J Cell Biol. 1990 Sep;111(3):1305–1311. doi: 10.1083/jcb.111.3.1305. [DOI] [PMC free article] [PubMed] [Google Scholar]
  127. Wimalawansa S. J. Combined therapy with estrogen and etidronate has an additive effect on bone mineral density in the hip and vertebrae: four-year randomized study. Am J Med. 1995 Jul;99(1):36–42. doi: 10.1016/s0002-9343(99)80102-8. [DOI] [PubMed] [Google Scholar]
  128. Wimalawansa S. J. Long- and short-term side effects and safety of calcitonin in man: a prospective study. Calcif Tissue Int. 1993 Feb;52(2):90–93. doi: 10.1007/BF00308314. [DOI] [PubMed] [Google Scholar]
  129. Wright C. D., Compston J. E. Tamoxifen: oestrogen or anti-oestrogen in bone? QJM. 1995 May;88(5):307–310. [PubMed] [Google Scholar]
  130. Wémeau J. L. Calciotropic hormones and ageing. Horm Res. 1995;43(1-3):76–79. doi: 10.1159/000184241. [DOI] [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES